RESEARCH INTERESTS
AREAS OF TECHNICAL EXPERTISE
1. HPLC/175/175
2. RIA
3. Receptor binding
RESEARCH EXPERTISE
Telephone: (352) 273-7861
Fax: (352) 273-7854
E-mail: hochhaus@cop.ufl.edu
SAMPLE PUBLICATIONS
Advances in single-entity inhaled corticosteroid therapy. Z. Tayab, G. Hochhaus, Allergy and Asthma Proceedings, 28, 125-135 (2007)What pharmacokinetic and pharmacodynamic properties are important for inhaled glucocorticoids? G. Hochhaus. Annals of Allergy, Asthma, & Immunology 98, S7-S15 (2007)
Pharmacokinetic/Pharmacodynamic Profile of Mometasone Furoate Nasal Spray: Potential Effects on Clinical Safety and Efficacy. G. Hochhaus. Clin. Therapeutics 30, 98-107 (2008) .
Laser-ablated nanofunctional polymers for the formulation of slow-release powders for dry powder inhalers: physicochemical characterization and slow-release characteristics . I. Coowanitwong, G. Patel, W-S Kim, V. Craciun, J. R. Rocca, R. R. Singh, and G. Hochhaus. J Pharmacy Pharmacol. 59, 1473-1484 (2007)
Plasma levels of fluticasone and budesonide following inhalation: effect of bronchoconstriction. K. Mortimer, T.W. Harrison, Y.T. K. Wu, S. Lewis, S. Sahasranaman, G. Hochhaus, A.E. Tattersfield. Br. J. Clin. Pharmacol. 64, 439-444 (2007)
Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate. Z.R. Tayab, T.C. Fardon, D.K.C. Lee, K. Haggart, L.C. McFarlane, B.J. Lipworth, G. Hochhaus. Br. J. 64, 698-705 (2007)
Pharmacokinetic/pharmacodynamic factors and steroid sensitivity. G. Hochhaus. Steroid Insensitivity. Edited by B. Adcock (in press).